Cargando…

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions

Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign breast disease (BBD) (n=263), proliferative BBD without atypia (n=128), proliferative BBD with atypia (n=11), carcinoma in situ (n=15) or invasive carcinoma (n=34) and for EG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terry, G, Ho, L, Londesborough, P, Duggan, C, Hanby, A, Cuzick, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360209/ https://www.ncbi.nlm.nih.gov/pubmed/17164758 http://dx.doi.org/10.1038/sj.bjc.6603512

Ejemplares similares

Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions
por: Terry, G, et al.
Publicado: (2002)

Expression of pendrin in benign and malignant human thyroid tissues
por: Skubis-Zegadło, J, et al.
Publicado: (2005)

Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3)
por: Houssami, N, et al.
Publicado: (2007)

Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer
por: Millican-Slater, Rebecca A, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions
por: Terry, G, et al.
Publicado: (2004)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease
por: Reis, I M, et al.
Publicado: (2015)

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
por: Pinder, S E, et al.
Publicado: (2010)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
por: Ahmed, N, et al.
Publicado: (2008)

Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers
por: Romanska, Hanna M, et al.
Publicado: (2015)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

ADM3, TFF3 and LGALS3 are discriminative molecular markers in fine-needle aspiration biopsies of benign and malignant thyroid tumours
por: Karger, S, et al.
Publicado: (2012)

Comparing the performance of six human papillomavirus tests in a screening population
por: Cuzick, J, et al.
Publicado: (2013)

Non-conventional role of haemoglobin beta in breast malignancy
por: Ponzetti, Marco, et al.
Publicado: (2017)

LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity
por: Morgan, R G, et al.
Publicado: (2018)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
por: Joosse, S A, et al.
Publicado: (2014)

Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus
por: Kaneko, K, et al.
Publicado: (2007)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Isolation of tumour stem-like cells from benign tumours
por: Xu, Q, et al.
Publicado: (2009)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Restored expression of Fhit protein in Fhit-minus breast cancer cells
por: Campiglio, M, et al.
Publicado: (2001)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
por: Van Laere, S J, et al.
Publicado: (2007)

Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays
por: Lawson, Jonathan, et al.
Publicado: (2017)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Nucleostemin mRNA is expressed in both normal and malignant renal tissues
por: Fan, Y, et al.
Publicado: (2006)

Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix
por: Erlandsson, F, et al.
Publicado: (2006)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases
por: Dzieȩgiel, P, et al.
Publicado: (2010)

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer
por: Ahmad, I, et al.
Publicado: (2013)

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
por: Kremer, R, et al.
Publicado: (2010)

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement
por: Foster, C S, et al.
Publicado: (2009)

Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands
por: Lujan, B, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u0j1qrpjogbt5t5ar7gacbn87h